Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2015

View Archived Issues

Eisai and Nihon Medi-Physics agree to collaborate on dementia research

Award supports development of entolimod for metastatic breast cancer

Potent in vitro activity of AP-138, a second-generation plectasin derivative

LEO Pharma returns rights to subcutaneous methotrexate for psoriasis to Antares

Rights to Parkinson's disease imaging agent returned to Alseres

Advanced Proteome Therapeutics' fusion protein inhibits tumor growth in animal model

NeurOp collaborates with Janssen to study modulation of NMDA receptor for CNS disorders

Facio Therapies and Evotec to discover drugs for facioscapulohumeral dystrophy

Preclinical and phase I clinical results for PXS-4728A

Roche and 4D Molecular Therapeutics enter AAV vector collaboration

Second Genome and APC Microbiome Institute form IBD alliance

CoLucid initiates first pivotal phase III trial of lasmiditan for migraine

ES Cell's embryonic stem cells to be used in UC Irvine Huntington's disease therapy

Phase I trial confirms anti-HCV activity of SB-9200

MediciNova reports interim results from study of ibudilast for ALS

RG-7800: safety and tolerability in humans

Promising first-in-human phase I safety and biodistribution results for 124I-PEG-AVP-0458

AstraZeneca profiles pipeline progress of first quarter 2015

Anti-inflammatory effects of amylin(28-33) described for the first time

FDA accepts for review Zinbryta BLA

European orphan drug designation granted to MANF for retinitis pigmentosa

Bristol-Myers Squibb patents mGlu5 receptor PAMs

Roche and Genentech present TRPA1 antagonists

Shanghai Yingli patents PI3Kdelta inhibitors

Wuhan Innerse introduces diphenylethanes for autoimmune diseases

Quanticel describes Brd4 inhibitors

Pembrolizumab combined with approved chemotherapeutics in phase I/II trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...